Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 175

1.

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC.

Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96.

PMID:
17005807
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.

Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M.

Mol Pharmacol. 2008 Mar;73(3):789-800. Epub 2007 Dec 20.

PMID:
18096812
[PubMed - indexed for MEDLINE]
Free Article
3.

Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.

Berro R, Klasse PJ, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP.

J Virol. 2011 Aug;85(16):8227-40. doi: 10.1128/JVI.00767-11. Epub 2011 Jun 15.

PMID:
21680525
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor.

Ji C, Zhang J, Dioszegi M, Chiu S, Rao E, Derosier A, Cammack N, Brandt M, Sankuratri S.

Mol Pharmacol. 2007 Jul;72(1):18-28. Epub 2007 Mar 28.

PMID:
17392523
[PubMed - indexed for MEDLINE]
Free Article
5.

Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.

Espirito-Santo M, Santos-Costa Q, Calado M, Dorr P, Azevedo-Pereira JM.

AIDS Res Hum Retroviruses. 2012 May;28(5):478-85. doi: 10.1089/AID.2011.0124. Epub 2011 Oct 3.

PMID:
21902586
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.

Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, Ahuja SK, Klasse PJ, Moore JP.

Virology. 2007 Aug 1;364(2):281-90. Epub 2007 Apr 10.

PMID:
17428518
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M.

Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32.

PMID:
16251317
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.

Li Z, Zhou N, Sun Y, Ray N, Lataillade M, Hanna GJ, Krystal M.

Antimicrob Agents Chemother. 2013 Sep;57(9):4172-80. doi: 10.1128/AAC.00513-13. Epub 2013 Jun 17.

PMID:
23774428
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.

Hu Q, Huang X, Shattock RJ.

J Gen Virol. 2010 Dec;91(Pt 12):2965-73. doi: 10.1099/vir.0.025270-0. Epub 2010 Sep 1.

PMID:
20810746
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP.

Virology. 2005 Jul 20;338(1):182-99.

PMID:
15935415
[PubMed - indexed for MEDLINE]
Free Article
11.

Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.

Henrich TJ, Lewine NR, Lee SH, Rao SS, Berro R, Gulick RM, Moore JP, Tsibris AM, Kuritzkes DR.

Antimicrob Agents Chemother. 2012 Apr;56(4):1931-5. doi: 10.1128/AAC.06061-11. Epub 2012 Jan 17.

PMID:
22252820
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.

Nolan KM, Del Prete GQ, Jordan AP, Haggarty B, Romano J, Leslie GJ, Hoxie JA.

J Virol. 2009 Apr;83(8):3798-809. doi: 10.1128/JVI.01751-08. Epub 2009 Feb 4.

PMID:
19193800
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T.

J Virol. 1999 May;73(5):4145-55.

PMID:
10196311
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC.

J Virol. 2001 Jan;75(2):579-88.

PMID:
11134270
[PubMed - indexed for MEDLINE]
Free PMC Article
15.
16.

Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.

Mulampaka SN, Dixit NM.

PLoS One. 2011;6(5):e19941. doi: 10.1371/journal.pone.0019941. Epub 2011 May 27.

PMID:
21647388
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M.

J Virol. 2007 Mar;81(5):2359-71. Epub 2006 Dec 20.

PMID:
17182681
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.

Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N.

Antimicrob Agents Chemother. 2013 May;57(5):2076-86. doi: 10.1128/AAC.02588-12. Epub 2013 Feb 12.

PMID:
23403432
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

[Viral entry as therapeutic target. Current situation of entry inhibitors].

Arenzana-Seisdedos F.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:5-11. Review. Spanish.

PMID:
19133215
[PubMed - indexed for MEDLINE]
20.

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.

Roche M, Jakobsen MR, Ellett A, Salimiseyedabad H, Jubb B, Westby M, Lee B, Lewin SR, Churchill MJ, Gorry PR.

Retrovirology. 2011 Nov 7;8:89. doi: 10.1186/1742-4690-8-89.

PMID:
22054077
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk